34 results about "Cortisone" patented technology

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

This disclosure provides a method for treating hair loss in a subject requiring treatment for hair loss, comprising topically administering an effective amount of cortexolone-17α-propionate and an effective amount of minoxidil to the subject. This disclosure further provides a topical pharmaceutical formulation comprising cortexolone-17α-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

The present disclosure provides methods of treating skin acne-like rash in a subject in need thereof. The method comprises applying an effective amount of picosterone-17 alpha-propionate to the surface of the subject. The acne-like rash may include papules, pustules, nodules, scabs, cysts, or any combination thereof on an affected area of the subject. An effective amount of the picosterone-17 [alpha]-propionate can be administered in a surface pharmaceutical formulation comprising the picosterone-17 [alpha]-propionate and one or more pharmaceutically acceptable carriers.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The application relates to the technical field of animal model construction, in particular to a construction method and application of a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model. The construction method comprises the following steps: a model group animal is subjected to modeling by adopting the method of senna leaf water decoction gavage and hydrocortisone and cyclophosphamide injection, and a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model is obtained. In the application, the three of senna leaf, hydrocortisone and cyclophosphamide are used in synergy to administer the animal model, and the complex syndrome of the clinical spleen-kidney yang deficiency type DOR is accurately reproduced, and modern scientific basis is provided for the theories of traditional Chinese medicine such as the same treatment for different diseases.

This invention relates to novel compounds of the Formula (1m1) wherein R1, R2, R3, A1, Cy1 and E are as defined in the specification, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds for use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

Orodispersible film (ODF) is an innovative drug formulation that allows for adjustable dosing and improved patient compliance. It is administered into the mouth where it dissolves, making it suitable for children. The present invention provides an optimized ODF gel formulation and an optimal ODF containing therapeutic doses of hydrocortisone-type corticosteroids (HTC). This ODF is thin, flexible and transparent, and suitable for production in hospital pharmacy using standard equipment. The ODF of the invention allows accurate hydrocortisone levels to be released systemically in patients in need thereof, and its good physico-chemical stability is herein demonstrated for several months. This opens up new opportunities for use in pediatric patients, notably for children suffering from congenital adrenal hyperplasia.

The application discloses a steroid C14 alpha hydroxylase CLCYP14 mutant, relates to the field of proteins, and applies a site-directed saturation mutation technology and a combination mutation strategy to screen and obtain CLCYP14 mutants I111L-M115K and I111L-V124W with high hydroxylation specificity. Compared with CLCYP14, the hydroxylation selectivity and conversion rate of I111L-M115K and I111L-V124W for steroid compounds progesterone, 21-hydroxyprogesterone, 5beta-hydroxyprogesterone, 1-dehydroprogesterone, 21-hydroxypregna-1,4-diene-3,20-dione and deoxycortisone are obviously improved.

This invention relates to a method for constructing and evaluating an animal model of Alzheimer's disease characterized by deficiency and blood stasis. Based on APP / PS1 mice, the model was induced by sleep deprivation, hydrocortisone, and carrageenan to induce qi deficiency, kidney deficiency, and blood stasis, respectively, for a total modeling period of 28 days, resulting in an animal model of Alzheimer's disease with deficiency and blood stasis. This model was constructed using a multi-factor combined approach, and its symptom manifestations are consistent with clinical observations. It is simple, effective, and easy to operate, providing a reliable experimental vehicle for the development of innovative drugs and the study of mechanisms of action in Alzheimer's disease with deficiency and blood stasis.

The application discloses a kind of serum-free epidermal melanocyte culture medium and its application, method includes by dissolving adenine, hepatocyte growth factor (HGF), glutamine, retinoic acid, vitamin E, nicotinic acid, sodium selenite, sodium hyaluronate and recombination human type XVII collagen are configured into initial culture medium;Preparation of melanocyte stimulating hormone, endothelin-3, transferrin, triiodothyronine, cholesterol, neuroregulin 1 (NRG1), 3-isobutyl-1-methyl purine (IBMX), dibutyryl cyclic adenosine monophosphate (db-cAMP), cholera toxin, hydrocortisone and recombination human insulin mother liquor;Step three: according to culture and concentration, a certain amount of mother liquor of step two is added to initial culture medium.The culture medium can effectively promote human epidermal melanocyte proliferation, melanin accumulation and help to promote human umbilical cord mesenchymal stem cells into human epidermal melanocyte, provide key advantage for obtaining functional melanocyte with high activity and therapeutic potential.

The invention relates to the technical field of biology, in particular to a dissociation agent and a kit for progesterone determination. According to the invention, the sample dissociation agent for progesterone detection is obtained through optimized screening, and the sample dissociation agent comprises hydrocortisone, prednisolone and mono (2-ethylhexyl) phthalate (MEHP); when the dissociation agent components act independently or in a combined mode, the sensitivity to sample detection is high, the detection linear range is good, the dissociation agent is well related to a comparison reagent, the dissociation effect is improved remarkably on the whole, progesterone can be better released from corticosteroid binding protein, albumin and sex hormone binding globulin, and the progesterone dissociation agent is suitable for being used for detecting progesterone. The combination of progesterone and a captured antibody is facilitated, and the sensitivity and the accuracy can be effectively improved. Moreover, the reagent can be directly added into reagent components, so that the dissociation process and the immune reaction are carried out at the same time, the immune reaction is simple and efficient, and the reaction efficiency is improved.

Long-acting resorbable subcutaneous implant with extended release of pre-concentrated pharmacologically active substance in polymer for treatment of chronic adrenal insufficiency. The implant is inserted subcutaneously and has continuous release of the active ingredient for an extended period of time. The implant may have in its constitution only hydrocortisone but is preferably formed by hydrocortisone particles homogeneously dispersed in a bio erodible and bioabsorbable polymer matrix. Such a polymer matrix may be formed of a polymer or a polymer blend. The release of the drug in this system occurs through diffusion, at a relatively constant rate, and it is possible to change the rate of release of the drug through the thickness or material of this membrane.

The application discloses a P450 enzyme mutant, a coding gene and application thereof in preparation of cortisone, and belongs to the technical field of bioengineering. The P450 enzyme mutant is obtained by amino acid mutation of CYP11B1 from Homo sapiens with an amino acid sequence shown as SEQ ID NO. 1, and the amino acid mutation site is at least one of S146V, H331D and L440F. The P450 enzyme mutant provided by the application has a higher soluble expression level in Escherichia coli than wild-type CYP11B1, the catalytic level of the constructed recombinant expression strain is higher, 11-deoxycortisol can be used as a substrate to prepare cortisone, the yield of the product is high, no by-product is generated, and the P450 enzyme mutant has a good industrial application prospect.

This invention relates to pharmaceutically acceptable salts, entantiomers or diastereomers of novel compounds of the Formula (Im1) wherein R1, R2, R3, A1, Cy1 and E are as defined in the specification, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention furhter relates to pharmaceutical compositions of the pharmaceutically acceptable salts, enantiomers or diastereomers of novel compounds for use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of methylprednisolone and an intermediate compound thereof. The preparation method comprises the following steps: by taking cortisone as a raw material, carrying out 17 and 21 site upper protecting groups and 3 site upper protecting groups, and carrying out reduction, so as to obtain a methylprednisolone intermediate compound shown as a formula V; and carrying out 5 and 6-site epoxidation, Grignard reaction, 3-site protecting group removal, 4 and 5-site dehydration elimination, 1 and 2-site dehydrogenation and 17 and 21-site protecting group removal on the compound in the formula V to obtain methylprednisolone. The structural formula of the compound of formula V is shown in the specification. The preparation process has the advantages of high yield, high purity, low cost, simplicity in operation and suitability for industrial production.

The application discloses an amplification culture medium and a culture method of human adult epidermal stem cells, and relates to the technical field of stem cell in-vitro culture. The culture medium comprises the following components: fibroblast growth factor, interleukin-6, insulin-like growth factor-1, epidermal growth factor, insulin, growth hormone, hydrocortisone, Y-27632, A83-01, Forsklin, PY60, CHIR99021, linoleic acid, linolenic acid, alanine, asparagine, glutamic acid, glycine, proline, serine, arginine, N-acetyl-L-cysteine, beta-mercaptoethanol and CaCl2. The culture medium can continuously and stably culture human adult epidermal stem cells for more than 20 generations, and a more stable long-term in-vitro amplification system of epidermal stem cells is established. After continuous subculture, the epidermal stem cells can maintain a high proliferation rate and multiple differentiation potential, and have the ability to construct multilayer skin.

The invention provides a culture medium and a culture method of normal oral fibroblasts. The culture medium comprises a DMEM (Dulbecco's Modified Eagle Medium) and the following components based on the volume of the DMEM: 10v% of Australian fetal calf serum, 2.5 ng / ml of bFGF (Basic Fibroblast Growth Factor), 1v% of a penicillin-streptomycin solution, 2.0 ug / ml of hydrocortisone and 0.05 ug / ml of FGF10 (Fibroblast Growth Factor 10). The invention solves the problems of high NF culture difficulty, easy pollution, low survival rate, incapability of permanent passage and the like, provides a basis for further exploring a mechanism for activating the NF into CAFs, is beneficial to finding and finding new therapeutic targets, and provides a new clinical diagnosis and treatment idea for treating and preventing the deterioration of the salivary gland benign tumor.

The application relates to the technical field of stem cells, in particular to a mesenchymal stem cell culture system without heterogeneity and application thereof. The mesenchymal stem cell culture system without heterogeneity comprises a basic culture medium and an additive component, wherein the basic culture medium is DMEM / F12, and the additive component comprises: recombinant human transferrin, recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin, recombinant human interferon gamma, hydrocortisone, vitamin A, vitamin D2, vitamin B, human blood albumin, CTS KnockOut SR XenoFree, glutamine and dextran. The mesenchymal stem cell culture system without heterogeneity provided by the application improves the proliferation efficiency of primary culture and in-vitro expansion culture of mesenchymal stem cells, is high in safety, good in stability and suitable for large-scale popularization and application.

This invention provides a method for detecting 21-aldehyde hydrocortisone. This method can accurately detect trace amounts of 21-aldehyde hydrocortisone in test samples (such as hydrocortisone or hydrocortisone sodium succinate), thereby achieving better quality control of the drug at the trace level and ensuring patient medication safety.

The invention relates to a serum-free culture medium and a preparation method and application thereof in the technical field of cell culture. The serum-free culture medium comprises a basic culture medium and the following components in final concentration: 5 to 15 ng / mL of dexamethasone, 200 to 600 ng / mL of hydrocortisone, 20 to 200 [mu] g / mL of transferrin, 0.2 to 1 mg / mL of human serum albumin, 40 to 70 [mu] M of beta-mercaptoethanol, 5 to 12 [mu] M of glutathione, 10 to 65 mg / L of ascorbic acid, 1 to 10 ng / mL of EGF, 1 to 20 ng / mL of IGF-1, 1 to 10 ng / mL of bFGF and 1 to 10 ng / mL of PDGF-BB. The basic culture medium is IMDM. According to the serum-free culture medium, an excellent culture effect can still be obtained by adding fewer culture medium components, the industrial production complexity is greatly reduced, the industrial production cost is reduced, and large-scale clinical requirements can be better met.

This invention belongs to the field of regenerative medicine, specifically relating to a lacrimal gland organoid culture medium and a method for in vitro culture of lacrimal gland organoids. In one aspect, a lacrimal gland stem cell proliferation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, and Noggin; the lacrimal gland stem cell basal culture medium comprises: DMEM medium, F12 medium, L-glutamine, fetal bovine serum, hydrocortisone, cholera toxin, B27, penicillin, streptomycin, amphotericin B, and fasudil. In another aspect, a lacrimal gland stem cell differentiation culture medium is provided, comprising: lacrimal gland stem cell basal culture medium, EGF, Wnt3a, FGF7, FGF10, RSP1, Noggin, and BMP7. The lacrimal gland organoids constructed by this invention are larger in volume than those of existing technologies, possessing numerous branched ducts and vesicular acinar structures, extending radially and multidirectionally in a three-dimensional manner, forming a complex and regular three-dimensional tubular acinar network, and possessing secretory function.

Topical compositions and kits are provided for hair regrowth, hair loss prevention, and scalp health improvement. These formulations contain at least one active (e.g., finasteride, minoxidil, dutasteride, and latanoprost), at least one penetration enhancer (e.g., Transcutol®, laurocapram), stabilizers, and anti-inflammatory agents like retinoic acid, hydrocortisone, and aloe vera. They utilize optimized particle sizes (D90 ≤8.5 μm, span ≤1.7) and may include bioadhesive polymers or nanoparticles for enhanced follicular delivery and extended residence. Modular kits offer multi-chambered packaging, calibrated droppers, and app- or sensor-guided dispensing for customizable ingredient mixing and regimen personalization. These innovations improve active stability, minimize irritation, and yield superior clinical outcomes (hair density and quality) over traditional therapies. Methods include treating varied alopecia types, with or without device-assisted delivery (microneedling, light therapy), alongside digital monitoring, compliance tracking, and optional diagnostic or conditioning tools for individualized scalp and hair care.

The invention belongs to the technical field of biology, and particularly relates to a culture medium capable of differentiating and inducing amniotic fluid cells into myoblasts, a method and application. The culture medium contains 5% v / v serum, 0.1 [mu] M of dexamethasone, 50 [mu] M of hydrocortisone, 1 [mu] M of MCHIR99021 and 5-10 ng / mL of IGF-1, and a solvent is a low-sugar DMEM (Dulbecco Modified Eagle Medium). According to the invention, amniotic fluid cells are separated from amniotic fluid, and myoblasts can be obtained by using the culture medium to culture, differentiate and induce. According to the invention, efficient muscle differentiation and RYR1 gene overexpression of amniotic fluid cells are realized for the first time, and the gene has high fidelity on splicing variation after induced differentiation, so that a safe, rapid and low-cost solution is provided for prenatal clear gene diagnosis.

The present invention provides methods and pharmaceutical compositions for treating subjects with hepatic fibrosis and / or cirrhosis. [Solution] A method is provided for treating a subject with hepatic fibrosis, comprising administering a pharmaceutical composition containing hydronidone or a salt thereof to the subject. Liver stiffness measurements and / or ishax scores may be used to identify a subject for treatment of hepatic fibrosis and / or cirrhosis.

Formulations comprising hydrocortisone are disclosed in a suppository for methods of treating ulcerative colitis and other gastrointestinal diseases and disorders. Administering a single hydrocortisone suppository once a day achieves remission or reduction of a symptom, optionally followed by a period of time in which the dosage is reduced.

Use of hydronidone in the preparation of a medicament for preventing and / or treating chronic kidney disease.

The invention discloses application of radix aconiti carmichaeli in treatment of kidney-yang deficiency type osteoporosis, and relates to the technical field of traditional Chinese medicine. The radix aconiti carmichaeli composition for treating the kidney-yang deficiency type osteoporosis comprises a radix aconiti carmichaeli extract and a pharmaceutically acceptable carrier, the radix aconiti carmichaeli extract is prepared through a water extraction or alcohol extraction method, the content of aconite alkaloids accounts for 1%-10% of the total weight of the extract, and the composition is prepared into an oral preparation or an injection. Through the synergistic effect of dual mechanisms of anti-aging and osteogenesis promotion, the problems of single target spot and limited curative effect of the traditional medicine are effectively solved; the radix aconiti carmichaeli can improve the kidney-yang deficiency state of the mouse caused by hydrocortisone injection, meanwhile, the cAMP / cGMP ratio tends to be normal, and the pathological internal environment of kidney-yang deficiency is turned on the whole.

The application provides a prostate cancer organoid special culture medium and a culture method thereof, and belongs to the technical field of biological medicine. The prostate cancer organoid special culture medium is composed of a basic culture medium and a culture additive. The basic culture medium does not contain exogenous added Noggin recombinant protein and R-spondin recombinant protein. The culture additive comprises basic fibroblast growth factor, keratinocyte growth factor, fibroblast growth factor 10, insulin, p38MAPK signal pathway inhibitor, insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, forskolin and androgen. The prostate cancer organoid special culture medium can reduce the cost and improve the culture success rate.

The present disclosure provides aqueous formulations comprising hydrocortisone sodium phosphate and monothioglycerol. In some embodiments, the formulations comprise monobasic sodium phosphate, dibasic sodium phosphate, or disodium EDTA. The present disclosure further provides a method of treating a disease or disorder in a subject by administering the aqueous formulation.

The invention relates to the field of biology, and provides a culture medium for cervical stomach type adenocarcinoma organs and application of the culture medium, the culture medium comprises a basic culture medium and an additive, and the additive comprises Neuregulin 1 and at least one of the following components: B27, Y-27632, estradiol, A83-01, EGF, Noggin, R-Spondin1, hydrocortisone, Forskolin and wnt3a. According to the present invention, with the organoid culture medium, the cervical stomach type adenocarcinoma organoid can be effectively obtained, and the cervical stomach type adenocarcinoma organoid can maintain the histomorphological characteristics of the original tumor tissue, can rapidly amplify and grow, and can be stably subjected to passage cryopreservation and resuscitation, such that the important research platform is provided for the personalized drug screening and treatment, and the application prospect is broad. The method has profound significance for scientific research and clinical application.